Stock News•1 months ago
Ginkgo Bioworks Q2 Earnings Call Highlights
Ginkgo Bioworks (NYSE: DNA) reported Q2 2026 revenue of $20 million, down 48% year over year, as it shifted focus toward autonomous lab systems, contract research, and software.
MarketLens
What Does Ginkgo Bioworks' Strategic Pivot Mean for Investors
4 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Category
You may also like
Stock News•2 months ago
Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?
Nvidia CEO Jensen Huang highlighted AI's potential in life sciences, backed by a partnership with Eli Lilly and an investment in Generate Biomedicines, signaling deeper healthcare market involvement.
News•2 months ago
Is Strategy Still a Bitcoin Proxy?
Strategy's corporate pivot has reshaped its market identity. The firm's Bitcoin-focused strategy raises questions about its proxy status for the cryptocurrency.
Breaking News
View All →Featured Articles
Top Headlines
Stock News•4 hours ago
Nvidia Is Weighing a $10 Billion Stake in Anthropic's IPO. It Would Be Buying Its Own Demand.
Stock News•8 hours ago
The 3 "Magnificent Seven" Stocks That I'm Buying Now
Stock News•8 hours ago
Live show: Amazon, Meta and the fight over the future of AI; Plus, is Seattle still the place to build?
Stock News•9 hours ago
Apple faces $5.7 billion patent infringement verdict over iPhone and Apple Watch haptics
Stock News•9 hours ago